Uniqure NV
QURE14.740USD
+0.580+4.10%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
808.72MValor de mercado
PerdaP/L TTM
Mais detalhes de Uniqure NV Empresa
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Informações da empresa
Código da empresaQURE
Nome da EmpresaUniqure NV
Data de listagemFeb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
Número de funcionários209
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 05
EndereçoPaasheuvelweg 25a
CidadeAMSTERDAM
Bolsa de valoresNASDAQ Global Select Consolidated
PaísNetherlands
Código postal1105 BP
Telefone31202406000
Sitehttps://www.uniqure.com/
Código da empresaQURE
Data de listagemFeb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
+57.56%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.66K
+10.77%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
20.27K
+40.66%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
15.67K
-22.96%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
+57.56%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.66K
+10.77%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 15 de ago
Atualizado em: sex, 15 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RTW Investments L.P.
9.40%
EcoR1 Capital, LLC
7.27%
Vestal Point Capital, LP
6.74%
Avoro Capital Advisors LLC
6.61%
abrdn Inc.
5.01%
Outro
64.96%
Investidores
Investidores
Proporção
RTW Investments L.P.
9.40%
EcoR1 Capital, LLC
7.27%
Vestal Point Capital, LP
6.74%
Avoro Capital Advisors LLC
6.61%
abrdn Inc.
5.01%
Outro
64.96%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
47.99%
Hedge Fund
20.71%
Investment Advisor
15.89%
Research Firm
7.48%
Corporation
4.35%
Venture Capital
3.60%
Individual Investor
1.71%
Private Equity
0.97%
Bank and Trust
0.29%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
396
55.26M
101.06%
-1.58M
2025Q1
429
55.29M
101.00%
-4.83M
2024Q4
431
46.57M
86.23%
-10.92M
2024Q3
431
43.93M
89.29%
-10.96M
2024Q2
435
37.07M
76.08%
-15.19M
2024Q1
449
38.56M
80.27%
-17.69M
2023Q4
454
43.54M
90.77%
-8.61M
2023Q3
462
41.52M
86.64%
-16.34M
2023Q2
452
41.43M
87.10%
-18.53M
2023Q1
454
47.06M
99.04%
-12.29M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RTW Investments L.P.
4.27M
7.79%
+3.36M
+372.04%
Mar 31, 2025
EcoR1 Capital, LLC
3.99M
7.29%
+588.97K
+17.32%
Mar 31, 2025
Vestal Point Capital, LP
4.79M
8.75%
+1.77M
+58.43%
Mar 31, 2025
Avoro Capital Advisors LLC
2.17M
3.97%
--
--
Mar 31, 2025
abrdn Inc.
2.22M
4.05%
+706.22K
+46.79%
Mar 31, 2025
Bristol Myers Squibb
2.39M
4.36%
--
--
Sep 30, 2024
Nantahala Capital Management, LLC
2.76M
5.03%
+302.60K
+12.33%
Mar 31, 2025
Franklin Advisers, Inc.
1.99M
3.63%
--
--
Mar 31, 2025
Two Sigma Investments, LP
1.58M
2.9%
-50.79K
-3.10%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
